FY2024 Earnings Forecast for PHIO Issued By HC Wainwright

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) – Analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of Phio Pharmaceuticals in a research report issued to clients and investors on Wednesday, February 19th. HC Wainwright analyst V. Bernardino expects that the company will post earnings per share of ($8.54) for the year. HC Wainwright currently has a “Buy” rating and a $4.00 price target on the stock. HC Wainwright also issued estimates for Phio Pharmaceuticals’ Q4 2024 earnings at ($1.23) EPS and FY2025 earnings at $3.76 EPS.

Phio Pharmaceuticals Trading Down 1.1 %

Phio Pharmaceuticals stock opened at $1.72 on Friday. The stock has a 50-day moving average price of $2.24 and a two-hundred day moving average price of $2.67. Phio Pharmaceuticals has a 12 month low of $1.53 and a 12 month high of $10.35.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Phio Pharmaceuticals stock. Virtu Financial LLC purchased a new stake in Phio Pharmaceuticals Corp. (NASDAQ:PHIO) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 40,910 shares of the company’s stock, valued at approximately $74,000. Virtu Financial LLC owned 0.59% of Phio Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 57.31% of the stock is owned by institutional investors and hedge funds.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.